The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk‐based management for their control
Open accessAbstract
The use of biological systems to synthesize complex therapeutic products has been a remarkable success. However, during product development, great attention must be devoted to defining acceptable levels of impurities that derive from that biological system, heading this list are host cell proteins (HCPs). Recent advances in proteomic analytics have shown how diverse this class of impurities is; as such knowledge and capability grows inevitable questions have arisen about how thorough current approaches to measuring HCPs are. The fundamental issue is how to adequately measure (and in turn monitor and control) such a large number of protein species (potentially thousands of components) to ensure safe and efficacious products. A rather elegant solution is to use an immunoassay (enzyme‐linked immunosorbent assay [ELISA]) based on polyclonal antibodies raised to the host cell (biological system) used to synthesize a particular therapeutic product. However, the measurement is entirely dependent on the antibody serum used, which dictates the sensitivity of the assay and the degree of coverage of the HCP spectrum. It provides one summed analog value for HCP amount; a positive if all HCP components can be considered equal, a negative in the more likely event one associates greater risk with certain components of the HCP proteome. In a thorough risk‐based approach, one would wish to be able to account for this. These issues have led to the investigation of orthogonal analytical methods; most prominently mass spectrometry. These techniques can potentially both identify and quantify HCPs. The ability to measure and monitor thousands of proteins proportionally increases the amount of data acquired. Significant benefits exist if the information can be used to determine critical HCPs and thereby create an improved basis for risk management. We describe a nascent approach to risk assessment of HCPs based upon such data, drawing attention to timeliness in relation to biosimilar initiatives. The development of such an approach requires databases based on cumulative knowledge of multiple risk factors that would require national and international regulators, standards authorities (e.g., NIST and NIBSC), industry and academia to all be involved in shaping what is the best approach to the adoption of the latest bioanalytical technology to this area, which is vital to delivering safe efficacious biological medicines of all types. Biotechnol. Bioeng. 2015;112: 1727–1737. © 2015 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
Current and future issues in the manufacturing and development of monoclonal antibodies
Kozlowski, S., & Swann, P. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.002 · Cited by 170 · cited 2×
“This is most likely an underestimation; a well characterized monoclonal antibody theoretically has the potential for (9,600)(2) post-translational modifications (Kozlowski and Swann, 2006).”
Background
Cited by
Rolinger, L., Rüdt, M., & Hubbuch, J. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02407-z · Cited by 126
Monitoring process-related impurities in biologics–host cell protein analysis
Pilely, K., Johansen, M. R., Lund, R. R., Kofoed, T., Jørgensen, T. K., Skriver, L., & Mørtz, E. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03648-2 · Cited by 78
Toward Biotherapeutic Product Real‐Time Quality Monitoring
Guerra, A., von Stosch, M., & Glassey, J. (2019) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2018.1524362 · Cited by 58
Characterization of AAV vectors: a review of analytical techniques and critical quality attributes
Kontogiannis, T., Braybrook, J., McElroy, C., Foy, C., Whale, A. S., Quaglia, M., & Smales, C. M. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101309 · Cited by 57
Self-citation
Metadata
- Authors
- Bracewell, D. G., Francis, R., & Smales, C. M.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2015-07-14
- Volume
- 112
- Issue
- 9
- Pages
- 1727-1737
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2121690674
- Cited by
- 184
- References
- 3
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk‐based management for their control. https://app.cochat.ai/papers/10.1002/bit.25628
- The paper
- Bracewell, D. G., Francis, R., & Smales, C. M. (2015). The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk‐based management for their control. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.25628
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.